FENBENDAZOLE and MEBENDAZOLE Testimonial – 77 year old Stage 4 Pancreatic Cancer patient sees 99.9% drop in CA19-9 levels and shrinkage of tumors by 70 to 87%! (2025)

Other · Makis W · April 2, 2025

Makis W, 2025-04-02: Patient testimonial published by William Makis describing a 77-year-old with stage 4 pancreatic cancer said to have had a 99.9% fall in CA19-9 and 70-87% tumour shrinkage on fenbendazole and mebendazole. The post is paywalled and the dose and co-treatments are not visible in the free preview.

FENBENDAZOLE and MEBENDAZOLE Testimonial – 77 year old Stage 4 Pancreatic Cancer patient sees 99.9% drop in CA19-9 levels and shrinkage of tumors by 70 to 87%!

n/a

Makis W, 2025-04-02: Patient testimonial published by William Makis describing a 77-year-old with stage 4 pancreatic cancer said to have had a 99.9% fall in CA19-9 and 70-87% tumour shrinkage on fenbendazole and mebendazole. The post is paywalled and the dose and co-treatments are not visible in the free preview. Patient-reported, not independently verified. Study type: testimonial published on Substack, not a peer-reviewed report. N=1. Country: not stated in the public preview. Drugs as stated in the title: fenbendazole and mebendazole. Dose: not visible in the free preview; Makis's published protocol (MBC-25) gives mebendazole 1,500 mg/day for high-grade cancers. Outcome as reported: CA19-9 down 99.9%, tumour shrinkage 70-87%. Measurement: not stated in the public preview (presumably imaging and CA19-9). Other treatments: not visible. Funder/conflicts: Makis sells subscriptions and consultations; recorded as neutral disclosure only. Full text is behind a Substack paywall; only the title and headline are verbatim. Study type: other.